Dialysis Access Stent Shows 92.7% Six-Month Patency

Dialysis patients with fistulas gain early real-world data on how a device keeps access circuits open.

Updated on Nov. 5, 2026 in Heart Disease

Isometric editorial illustration of a matte cylindrical lattice tube with an open central channel, rendered in oxblood and deep teal against a plain field.
Merit Medical Systems reported that its WRAPSODY stent kept dialysis access circuits open in 92.7% of patients at six months, based on real-world registry data. AI Illustration. Upload story photo >

Merit Medical Systems reported real-world patency results from the AVF cohort of its WRAP Global Registry, tracking the WRAPSODY Cell-Impermeable Endoprosthesis in dialysis access patients. The data were presented at the CiDA conference in Washington, DC, and are relevant to people with kidney failure who rely on arteriovenous fistulas for hemodialysis.

Why it matters

Dialysis access circuits often narrow or close over time, requiring repeat procedures that can interrupt treatment. Real-world registry data help show how a device performs in routine care, not just in controlled trial conditions, which is useful for clinicians and patients weighing access options.

This is a prospective, international, multicenter real-world registry tracking 237 AVF patients across 31 sites in nine countries. Six-month primary patency was 92.7% for target lesions and 76.7% for access circuits, compared with 89.8% and 72.8% in the WAVE pivotal trial's AVF cohort; the registry tracks outcomes for 24 months after placement.

The players

Merit Medical Systems

A medical device company based in South Jordan, Utah, with a portfolio of products for interventional cardiology, radiology, and dialysis access, and the maker of the WRAPSODY CIE.

The details

The WRAPSODY Cell-Impermeable Endoprosthesis is a stent-like device placed inside a blood vessel to keep it open for dialysis access. The WRAP Global Registry observes how the device performs in routine clinical practice outside a traditional trial setting, capturing outcomes across a broader range of patients and clinical conditions. Results were presented during the New Innovations, Trials, Techniques & Devices session at the CiDA conference.

Timeline

  1. December 2024: FDA granted premarket approval for the WRAPSODY CIE.

  2. January 2025: Merit began commercializing the device in the United States.

  3. April 2025: Health Canada approved the WRAPSODY CIE.

  4. October 31, 2026: Clinical data were presented at the CiDA conference in Washington, DC.

  5. November 5, 2026: Merit announced the registry results.

Health Landscape

The WAVE pivotal trial provided the controlled evidence behind the device's approvals in the United States and Canada. This registry extends that evidence into everyday clinical use, adding real-world data to the trial-based record for dialysis access devices.

If you are on hemodialysis or are discussing vascular access options with your care team, these results show how one device has performed in routine practice across several countries. Patients and clinicians can ask their nephrology or vascular team whether this approach is appropriate for their situation.

The takeaway

Real-world registry data add useful evidence beyond controlled trials for dialysis access devices. Anyone managing kidney failure should discuss vascular access options and follow-up monitoring with their nephrology team.

What happens next

Merit expects the combined data from the WAVE trial, the WRAP North America registry, and the WRAP Global registry to build the largest single-indication cohort in dialysis access to date, and the North America registry is designed to enroll up to 250 patients in the United States and Canada.

Further reading

For broader context on the vascular system and circulation, explore our Heart Disease coverage.

More information

Review the WRAPSODY CIE product information for United States on the Merit Medical website.

Source note: This article includes information reported by The Manila times.